AbbVie has decided it can do without Caribou Biosciences. The Big Pharma is terminating its off-the-shelf CAR-T pact with the biotech, depriving Caribou of the chance to pocket up to $350 million in milestones per program.

AbbVie决定不需要驯鹿生物科学。这家大型制药公司正在终止其与生物技术公司签订的现成CAR-T协议，从而剥夺了驯鹿在每个项目中获得高达3.5亿美元里程碑的机会。

Caribou found out AbbVie is walking away from the alliance this week. According to the biotech, AbbVie’s decision to terminate the deal was based on its “strategic focus” and was unrelated to Caribou’s performance or data generated so far. The action continues a busy period of partner pruning at AbbVie, which has axed alliances with Harpoon Therapeutics and I-Mab in the past two weeks..

驯鹿本周发现艾伯维正在退出联盟。据该生物技术公司称，艾伯维终止交易的决定是基于其“战略重点”，与驯鹿的表现或迄今为止产生的数据无关。这一行动延续了AbbVie合作伙伴修剪的繁忙时期，该公司在过去两周内取消了与Harpoon Therapeutics和I-Mab的联盟。。

AbbVie partnered with Caribou early in 2021, when it paid $30 million upfront and invested $10 million in the biotech to collaborate on two CAR-T programs. Caribou framed the deal as external recognition of the potential of its Cas12a chRDNA technology to improve genome-editing specificity and efficiency..

2021年初，AbbVie与Caribou合作，当时它预付了3000万美元，并在生物技术领域投资了1000万美元，合作开发了两个CAR-T项目。Caribou将该交易定义为外部认可其Cas12a chRDNA技术在提高基因组编辑特异性和效率方面的潜力。。

Caribou was in line to receive up to $150 million in developmental, regulatory and commercialization milestones, plus up to $200 million in sales-based milestones, per program. AbbVie chose targets for two programs and reserved two additional targets, which it could substitute into the two initial programs or use in two additional programs under an expanded collaboration..

Caribou在每个项目的开发、监管和商业化里程碑中获得了高达1.5亿美元的资金，另外在销售里程碑中获得了高达2亿美元的资金。AbbVie为两个项目选择了目标，并保留了另外两个目标，它可以将其替换为两个初始项目，或者在扩展的合作下用于另外两个项目。。

But rather than advance the programs, AbbVie has decided to terminate the deal and return all licenses to Caribou. The action leaves Caribou focused on an internal pipeline led by allogeneic CAR-T cell therapies against CD19 and BCMA. Both candidates are in the clinic and could provide an off-the-shelf alternative to existing cell therapies such as Gilead’s Yescarta and Johnson & Johnson’s Carvykti..

但AbbVie没有推进这些项目，而是决定终止交易，并将所有许可证退还给驯鹿。该行动使驯鹿专注于由针对CD19和BCMA的同种异体CAR-T细胞疗法领导的内部管道。两位候选人都在诊所，可以提供现有细胞疗法的现成替代品，如吉利德的Yescarta和强生的Carvykti。。

Pfizer stepped up to help fund the pipeline in July, investing $25 million in Caribou. The biotech earmarked the cash for clinical development of its allogeneic anti-BCMA CAR-T cell therapy, dubbed CB-011.

7月，辉瑞公司（Pfizer）加大资金支持力度，向北美驯鹿（Caribou）投资2500万美元。该生物技术公司将资金专门用于其同种异体抗BCMA CAR-T细胞疗法（称为CB-011）的临床开发。